Market Overview

EntreMed Initiates Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

EntreMed (NASDAQ: ENMD) announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC).  Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study.  Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway.  This study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.  More information about the clinical trial can be found at www.ClinicalTrials.gov.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "The primary objective of this Phase 2 trial is to assess clinical benefits of ENMD-2076 in TNBC patients.  In addition, it will also test in a clinical setting the correlation between patient responses to ENMD-2076 and p-53 based genomic profiling predictive biomarker that was identified in pre-clinical studies by Dr. Jennifer Diamond and her group at the University of Colorado Cancer Center. This Phase 2 trial is therefore valuable to us and it may provide critical guidance on our next phase of clinical trials.  The study at our first

See full press release

Posted-In: News Guidance Contracts Management

 

Most Popular

Related Articles (ENMD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters